Bivalirudin 128270-60-0
| Systematic (IUPAC) name: |
(15S,21S,24S,27S,30S) - 15 - (2-amino-2-oxoethyl) - 1 - [(2S)-1-{(2S)-2-[({(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl} carbonyl)amino]-5-carbamimidamidopentanoyl}pyrrolidin-2-yl] - 24 - benzyl-30-({(2S,3S)-1-[(2S)-2 -{[(2S)-4-carboxy - 1 - {[(2S)-4-carboxy-1-{[(2S)-1-{[(1S)-1-carboxy-3-methylbutyl]amino}-3 -(4-hydroxyphenyl) - 1 - oxopropan-2-yl]amino} - 1 - oxobutan-2-yl]amino}-1-oxobutan-2-yl]carbamoyl}pyrroli din -1-yl]-3-methyl - 1 - oxopentan-2-yl}carbamoyl) - 27 - (2-carboxyethyl) - 21 - (carboxymethyl) - 1,4,7,10,13,16,19,22, 25,28 - decaoxo-2,5,8,11,14,17,20,23,26,29 - decaazatritriacontan - 33 - oic acid |
| Bivalirudin CAS number: |
128270-60-0 |
| ATC code: |
B01AE06 |
| PubChem: |
16129704 |
| DrugBank: |
|
| Formula: |
C98H138N24O33 |
| Molecular mass: |
2180.29 g/mol |
| Bivalirudin Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
